Exchange Traded Concepts LLC Grows Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Exchange Traded Concepts LLC raised its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 4.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 23,776 shares of the company’s stock after acquiring an additional 975 shares during the period. Exchange Traded Concepts LLC’s holdings in Prestige Consumer Healthcare were worth $1,857,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in shares of Prestige Consumer Healthcare by 3.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock valued at $19,630,000 after buying an additional 8,533 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Prestige Consumer Healthcare by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,326,794 shares of the company’s stock valued at $95,678,000 after buying an additional 50,961 shares in the last quarter. Sequoia Financial Advisors LLC raised its holdings in shares of Prestige Consumer Healthcare by 12.9% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock valued at $708,000 after buying an additional 1,120 shares in the last quarter. Barclays PLC raised its holdings in shares of Prestige Consumer Healthcare by 346.3% during the 3rd quarter. Barclays PLC now owns 92,444 shares of the company’s stock valued at $6,665,000 after buying an additional 71,730 shares in the last quarter. Finally, Pinnacle Associates Ltd. raised its holdings in shares of Prestige Consumer Healthcare by 60.3% during the 3rd quarter. Pinnacle Associates Ltd. now owns 24,630 shares of the company’s stock valued at $1,776,000 after buying an additional 9,269 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

PBH opened at $76.79 on Monday. The firm has a market cap of $3.79 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 2.17 and a beta of 0.51. Prestige Consumer Healthcare Inc. has a 1 year low of $60.00 and a 1 year high of $86.36. The stock’s 50 day simple moving average is $80.08 and its 200 day simple moving average is $74.93. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.09. The firm had revenue of $283.79 million for the quarter, compared to analyst estimates of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business’s quarterly revenue was down .9% compared to the same quarter last year. During the same period last year, the company earned $1.07 EPS. As a group, analysts predict that Prestige Consumer Healthcare Inc. will post 4.46 earnings per share for the current year.

Insider Transactions at Prestige Consumer Healthcare

In related news, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the sale, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the sale, the insider now owns 20,058 shares in the company, valued at $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on PBH. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research report on Friday. DA Davidson restated a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Finally, Raymond James upgraded Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $85.25.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.